Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

A Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib in Patients with Myelofibrosis (MF) and Baseline Platelet Counts from 50 × 10 9 /L to 99 × 10 9 /L (The EXPAND Study)

Peter te Boekhorst, MD PhD, Claire N. Harrison, DM, FRCP, FRCPath, Heinz Gisslinger, MD PhD, Dietger Niederwieser, MD, Viktoriya Stalbovskaya, PhD, Edric Atienza, MSHS, Prashanth Gopalakrishna, MBBS, MRCS, Alessandro M. Vannucchi, MD

Blood (2014) 124 (21): 1841.

https://doi.org/10.1182/blood.V124.21.1841.1841

Published: 2014

Journal Articles

AOP2014, a Novel Peg-Proline-Interferon Alpha-2b with Improved Pharmacokinetic Properties, Is Safe and Well Tolerated and Shows Promising Efficacy in Patients with Polycythemia Vera (PV)

Heinz Gisslinger, MD, PhD, Robert Kralovics, Bettina Gisslinger, Daniel Lechner, MD, Veronika Buxhofer-Ausch, MD, Karin Strecker, MD, Guenther Gastl, MD, Ella Willenbacher, MD, Richard Greil, MD, Alexander Egle, MD, Thomas Melchardt, MD, Sonja Burgstaller, MD, Ernst Schloegl, MD, Franz-Josef Tarmann, MSc, Michael Zoerer, PhD, Christoph Klade, PhD, Oleh Zahriychuk, MD, Josef Thaler, MD

Blood (2012) 120 (21): 175.

https://doi.org/10.1182/blood.V120.21.175.175

Published: 2012

Journal Articles

The Tetraspanin CD9 Is Involved in Primary Myelofibrosis Dysmegakaryopoiesis Through c-Myb Regulation and Stroma Interactions,

Christophe Desterke, PhD, Costanza Bogani, PhD, Lisa Pieri, MD, Alessandro M. Vannucchi, MD, PhD, Bernadette Guerton, Christophe Martinaud, MD, Denis Clay, Jean-Jacques Lataillade, MD, PhD, Hans Hasselbalch, MD, PhD, Heinz Gisslinger, MD, PhD, Sophie Amsellem, PhD, Jean-Loup Demory, MD, Agnès Charpentier, MD, Brigitte Dupriez, Claude Boucheix, MD, PhD, Eric Rubinstein, PhD, Marie-Caroline Le Bousse-Kerdiles, PhD

Blood (2011) 118 (21): 3834.

https://doi.org/10.1182/blood.V118.21.3834.3834

Published: 2011

Journal Articles

FLT3-Mediated MAPK Activation Participates in the Control of Megakaryopoiesis in Primary Myelofibrosis.

Christophe Desterke, Chrystele Bilhou-Nabera, MD, PhD, Bernadette Guerton, Carole Tonetti, Denis Clay, Olivier Pierre-Louis, Alessandro M Vannucchi, MD, PhD, Heinz Gisslinger, MD, PhD, Dominique Bordessoule, MD, PhD, Hans C Hasselbalch, MD, PhD, Vladimir Lazar, PhD, William Vainchenker, MD, PhD, Annelise Bennaceur-Griscelli, MD, PhD, Stéphane Giraudier, MD, PhD, Marie-Caroline Le Bousse-Kerdilès, PhD

Blood (2009) 114 (22): 963.

https://doi.org/10.1182/blood.V114.22.963.963

Published: 2009

Journal Articles

FLT3 Mediated MAPK Activation Participates in the Control of Megakaryopoiesis in Primary Myelofibrosis

Christophe Desterke, Hans Hasselbalch, MD, PHD, Dominique Bordessoule, MD, PhD, Heinz Gisslinger, MD, PhD, Alessandro Vannucchi, MD, PhD, Olivier Pierre-Louis, Carole Tonetti, Philippe Dessen, PhD, Vladimir Lazar, MD, PhD, Bernadette Guerton, Denis Clay, William Vainchenker, MD, PhD, Stephane Giraudier, MD, PhD, Marie-Caroline Le Bousse-Kerdiles, PhD

Blood (2007) 110 (11): 1532.

https://doi.org/10.1182/blood.V110.11.1532.1532

Published: 2007

NARROW

A Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib in Patients with Myelofibrosis (MF) and Baseline Platelet Counts from 50 × 10 9 /L to 99 × 10 9 /L (The EXPAND Study)

AOP2014, a Novel Peg-Proline-Interferon Alpha-2b with Improved Pharmacokinetic Properties, Is Safe and Well Tolerated and Shows Promising Efficacy in Patients with Polycythemia Vera (PV)

The Tetraspanin CD9 Is Involved in Primary Myelofibrosis Dysmegakaryopoiesis Through c-Myb Regulation and Stroma Interactions,

FLT3-Mediated MAPK Activation Participates in the Control of Megakaryopoiesis in Primary Myelofibrosis.

FLT3 Mediated MAPK Activation Participates in the Control of Megakaryopoiesis in Primary Myelofibrosis

Email alerts

ASH Publications

American Society of Hematology

A Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib in Patients with Myelofibrosis (MF) and Baseline Platelet Counts from 50 × 10 9 /L to 99 × 10 9 /L (The EXPAND Study)

AOP2014, a Novel Peg-Proline-Interferon Alpha-2b with Improved Pharmacokinetic Properties, Is Safe and Well Tolerated and Shows Promising Efficacy in Patients with Polycythemia Vera (PV)

The Tetraspanin CD9 Is Involved in Primary Myelofibrosis Dysmegakaryopoiesis Through c-Myb Regulation and Stroma Interactions,

FLT3-Mediated MAPK Activation Participates in the Control of Megakaryopoiesis in Primary Myelofibrosis.

FLT3 Mediated MAPK Activation Participates in the Control of Megakaryopoiesis in Primary Myelofibrosis

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only